CRYO CELL INTERNATIONAL INC

Listed Company

CCELCIK 0000862692NYSENon-AcceleratedSmaller ReportingServices-Misc Health & Allied Services, NecDelawareFY ends Nov 30

Period

FY 2025

Revenue

—

Net Income

$-2.43M

Total Assets

$61.73M

Equity

$-18.61M

Shares Out

8.06M

Op. Cash Flow

$5.48M

CCEL$3.42−31.46% · past yearDBEQ Basic

Daily closing prices

Business

Cryo-Cell International is a cellular preservation company that collects, processes and cryogenically stores umbilical cord blood and cord tissue stem cells for family and public use. The company manufactures the PrepaCyte CB processing system for cord blood stem cell processing and operates a public cord blood banking service. Cryo-Cell operates through three reportable segments: family cord blood and tissue storage, manufacturing of processing equipment, and public cord blood banking; it also offers third-party cold storage services (ExtraVault) and maintains over 250,000 preserved specimens worldwide through facilities in Florida and North Carolina.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Revenue	32	32	31	30	29
Cost of sales	7	8	8	9	9
Selling, general and administrative expenses	18	19	17	16	15
Impairment of public inventory	4	0	4	0	1
Research, development and related engineering	376,263	1	1	384,789	49,870
Depreciation and amortization	751,474	483,522	1	1	834,845
Total costs and expenses	31	29	44	26	25
Operating Income	482,394	3	−12	4	4
(Losses) gains on marketable securities	−806,267	1	50,777	−38,972	−13,064
Gain on interest rate swap	0	105,887	122,113	446,200	0
Other income	52,976	6,583	3,441	1,676	99
Interest expense	−2	−2	−1	—	—
Total other (expense) income	−3	−676,163	−1	−705,519	−1
(Loss) income before income tax expense	−2	3	−13	3	3
Income tax expense	−92,232	−2	4	−547,540	−527,710
Net (loss) income	−2	402,095	−10	3	2
Net (loss) income per common share - basic	−0.3	0.05	−1.14	0.33	0.26
Weighted average common shares outstanding - basic	8	8	8	8	8
Net (loss) income per common share - diluted	−0.3	0.05	−1.14	0.33	0.25
Weighted average common shares outstanding - diluted	8	8	8	8	8

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Cash and cash equivalents	319,031	560,960	406,067	2	8
Marketable securities	3	3	574,183	17,620	75,412
Accounts receivable (net of allowance for doubtful accounts of $4,306,410 and $4,266,405, respectively)	7	7	7	6	5
Prepaid expenses	573,218	637,055	615,407	566,557	558,413
Inventory, current portion	408,794	657,703	768,877	851,230	921,213
Other current assets	633,985	454,598	389,950	426,879	711,208
Total current assets	12	13	9	10	16
Property and Equipment-net	21	22	21	14	3
Intangible assets, net	863,074	921,254	989,121	1	2
Inventory, net of current portion	776,000	5	5	9	10
Goodwill	2	2	2	2	2
Deferred tax assets	24	21	20	14	12
Operating lease right-of-use asset	819,626	806,339	1	606,034	916,493
Deposits and other assets, net	915,099	815,635	746,493	647,226	566,470
Total other assets	29	30	31	42	42
Total assets	62	65	61	65	61
Accounts payable	3	2	3	2	1
Accrued expenses	4	6	5	4	3
Note payable	183,650	170,488	165,641	150,527	2
Line of credit	2	4	1	2	0
Current portion of operating lease liability	430,221	428,334	225,686	297,691	312,067
Deferred revenue	10	10	10	10	9
Total current liabilities	20	22	21	19	21
Deferred revenue, net of current portion	51	47	41	36	31
Note payable, net of current portion and debt issuance costs	8	8	8	9	0
Operating lease long-term liability	474,628	505,053	851,938	313,298	610,989
Long-term liability - revenue sharing agreements	875,000	875,000	875,000	875,000	875,000
Other liabilities	47,020	47,020	—	—	—
Total other liabilities	61	56	51	47	35
Total liabilities	80	78	72	66	56
Commitments and contingencies (Note 12)	0	0	0	0	0
Preferred stock	0	0	0	0	0
Common stock ($.01 par value, 20,000,000 authorized; 14,877,119 issued and 8,055,150 outstanding as of November 30, 2025 and 14,869,619 issued and 8,082,159 outstanding as of November 30, 2024)	148,771	148,696	148,492	148,480	146,658
Additional paid-in capital	45	44	43	43	42
Treasury stock, at cost	−25	−25	−23	−23	−21
Accumulated deficit	−38	−33	−31	−22	−17
Total stockholders' deficit	−19	−13	−11	−2	4
Total liabilities and stockholders' deficit	62	65	61	65	61

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Net (loss) income	−2	402,095	−10	3	2
Depreciation and amortization expense	985,242	693,847	1	1	1
Impairment of investment - Tianhe stock	0	308,000	0	—	—
Loss on sale of property and equipment	48,304	0	—	—	15,111
Unrealized gain on interest rate swap contract	0	−105,887	−122,113	0	—
Compensatory element of stock options	417,101	781,128	816,639	461,345	301,616
Provision for doubtful accounts	868,795	1	868,795	929,618	536,999
Deferred income tax benefit	−3	−309,274	−7	−2	−2
Amortization of debt issuance costs	20,822	21,237	21,631	15,834	56,851
Amortization of operating lease right-of-use asset	382,876	327,750	310,744	310,459	287,287
Accounts receivable	−405,881	−2	−2	−2	532,788
Prepaid expenses	63,837	−21,648	−48,850	−8,144	53,214
Inventory	56,190	429,178	360,445	490,002	210,277
Other current assets	−179,387	−64,648	36,929	284,329	−466,512
Deposits and other assets, net	−99,464	−69,142	−99,267	−80,756	15,549
Accounts payable	1	−423,720	688,935	115,527	532,384
Accrued expenses	−2	639,063	2	528,424	11,275
Operating lease liability	−424,701	−245,169	−271,232	−312,067	−280,837
Other liabilities	0	2,794	—	—	—
Deferred revenue	4	5	5	5	4
Net cash from operating activities	5	6	9	9	8
Purchases of property and equipment	−230,475	−2	−7	−12	−2
Sale of property and equipment	115,000	0	0	2	0
Payment of Duke license agreement	0	−1	−799,999	−5	−5
Proceeds from liquidation of marketable securities	0	101,873	179,306	0	—
Purchases of marketable securities	−4	−3	−1	−1	0
Sale of marketable securities	3	2	397,831	1	0
Net cash used in investing activities	−975,332	−5	−8	−15	−7
Treasury stock purchases	−169,502	−1	−799,036	−2	−249,377
Repayments of note payable	−147,575	−136,382	−156,355	−2	−4
Repayment of line of credit	−10	−3	−2	−5	0
Proceeds from the exercise of stock options	23,101	76,402	0	551,274	1
Proceeds from line of credit	9	5	950,000	8	0
Dividends paid	−3	−2	0	−8	0
Proceeds from Swap termination	0	228,000	0	—	—
Net cash used in financing activities	−5	−979,118	−2	147,862	−3
(Decrease) increase in cash and cash equivalents	−241,929	154,893	−1	−7	−2
Lease liability arising from right-of-use asset	396,163	100,932	737,867	0	904,691
Construction costs payable	0	−880,348	880,348	0	—
Interest	2	2	2	1	1
Income taxes	5	3	2	2	4

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CRYO CELL INTERNATIONAL INC's CIK number?

CRYO CELL INTERNATIONAL INC's SEC CIK number is 0000862692 (862692). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CRYO CELL INTERNATIONAL INC's SEC filings?

All of CRYO CELL INTERNATIONAL INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CRYO CELL INTERNATIONAL INC last report earnings?

CRYO CELL INTERNATIONAL INC (CCEL) most recently filed an earnings 8-K with the SEC on Oct 17, 2024, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000950170-24-115106). This is CRYO CELL INTERNATIONAL INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is CRYO CELL INTERNATIONAL INC's most recent earnings 8-K?

CRYO CELL INTERNATIONAL INC's latest earnings 8-K (Item 2.02) was filed Oct 17, 2024 under accession 0000950170-24-115106. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CRYO CELL INTERNATIONAL INC's latest earnings 8-K →
Look up any company's CIK number →